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ABSTRACT: Glioblastoma multiforme is the most aggressive
brain tumor, due to its high invasiveness and genetic heterogeneity.
Moreover, the blood−brain barrier prevents many drugs from
reaching a therapeutic concentration at the tumor site, and most of
the chemotherapeutics lack in specificity toward cancer cells,
accumulating in both healthy and diseased tissues, with severe side
effects. Here, we present in vitro investigations on lipid-based
nanovectors encapsulating a drug, nutlin-3a, and superparamag-
netic iron oxide nanoparticles, to combine the proapoptotic action
of the drug and the hyperthermia mediated by superparamagnetic
iron oxide nanoparticles stimulated with an alternating magnetic
field. The nanovectors are functionalized with the peptide
angiopep-2 to induce receptor-mediated transcytosis through the
blood−brain barrier and to target a receptor overexpressed by glioma cells. The glioblastoma multiforme targeting efficiency and the
blood−brain barrier crossing abilities were tested through in vitro fluidic models, where different human cell lines were placed to
mimic the tumor microenvironment. These nanovectors successfully cross the blood−brain barrier model, maintaining their
targeting abilities for glioblastoma multiforme with minimal interaction with healthy cells. Moreover, we showed that nanovector-
assisted hyperthermia induces a lysosomal membrane permeabilization that not only initiates a caspase-dependent apoptotic
pathway, but also enhances the anticancer efficacy of the drug.
KEYWORDS: glioblastoma multiforme, active targeting, lipid nanoparticles, superparamagnetic iron oxide nanoparticles,
blood−brain barrier, lysosomal membrane permeabilization
■ INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and
aggressive tumor of the central nervous system, with an
incidence of two to three cases per 100 000 people worldwide1
and a median survival of just about 1.5 years after diagnosis.
The current standard treatment consists of a combination of
surgical resection, radiotherapy, and chemotherapy; however, it
only minimally extends the average patient survival.2 This poor
outcome is due to the complexity of the tumor, its genetic
heterogeneity,3 and its topological invasive nature that make
the complete surgical resection almost impossible. Moreover,
most of the conventional chemotherapeutics are unable to
cross the blood−brain barrier (BBB) and to reach a
satisfactory therapeutic concentration within the brain.4
Nevertheless, even if the drug diffuses through the BBB, its
unselective distribution and poor specificity toward the desired
site of action may cause severe side effects to the delicate
environment of the central nervous system.5
Given this scenario, it is clear that there is an urgent need to
design alternative therapies for the treatment of GBM. An ideal
therapeutic approach should consist of a system able to deliver
its pharmaceutical cargo, to penetrate through the BBB, and,
finally, to selectively target the diseased tissues without
affecting the healthy ones.6 In this context, nanomedicine
made huge progresses in improving the systemic delivery of
drugs, increasing their bioavailability, and protecting them
from enzymatic digestion.7 Nanoparticles are also known to
accumulate in tumor tissues due to the enhanced permeability
and retention (EPR) effect;8 however, this form of passive
targeting is difficult to control and can induce multidrug
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resistance (MDR).9 Active targeting, instead, relies on a more
specific interaction between a ligand, attached on the surface of
the nanoparticles, and particular receptors overexpressed on
the target tissues but minimally expressed on healthy cells.10
Many ligands have been exploited for this purpose, but
peptides present several advantages compared to the others,
such as high stability, low immunogenicity, and simple
production.6,7
In this work, we focused on the study of the targeting
abilities and the potential therapeutic efficacy of a lipid-based
nanovector functionalized with angiopep-2, a peptide derived
from the Kunitz domain of aprotinin,11 that binds to the low-
density lipoprotein receptor-related protein 1 (LRP1), overex-
pressed on glioma cell surface.10 LRP1 is also present on brain
capillary endothelial cells (BCECs);12 therefore, angiopep-2
should be also able to favor the penetration of the BBB via
receptor-mediated transcytosis.13 Our nanovector is composed
of a matrix of biocompatible lipids, encapsulating both
superparamagnetic iron oxide nanoparticles (SPIONs) and a
nongenotoxic drug, nutlin-3a. The latter is an antagonist of the
murine double minute-2 (MDM2) protein, a negative
regulator of the tumor suppressor protein p53, that inhibits
its transcriptional activity14 and stimulates its degradation.15
According to The Cancer Genome Atlas (TCGA), 85.3% of
GBM presents alterations of the p53 pathway, among which
27.9% are mutation/deletion of the TP53 gene, 7.6% are
amplification of the MDM2 protein, and the majority (57.8%)
consists in the deletion of the CDKN2A gene that codes for the
p14ARF protein, a physiological inhibitor of the MDM2
protein.16 Therefore, an overexpression of the MDM2 protein
is directly related to cancer development.14 The ability of
nutlin-3a to inhibit the MDM2-p53 interaction is of extreme
importance in the reactivation of the p53 pathway.14
Moreover, MDM2 inhibitors have a significantly lower toxicity
to healthy cells with respect to other drugs, making them
interesting options for cancer therapy.14,15 The other
components of the proposed nanoplatform, SPIONs, are well
known in the literature to induce cell apoptosis through
hyperthermia after stimulation with an alternating magnetic
field (AMF).17,18 This mechanism occurs regardless of the type
of cell, but its effectiveness depends mainly on the actual
concentration and compartment localization of the SPIONs
within the intracellular environment.19 The efficacy of this
treatment increases when combined with conventional chemo-
therapeutic drugs.17
Here, we demonstrated that angiopep-2-functionalized lipid-
based magnetic nanovectors (Ang-LMNVs) have a strong
affinity for glioblastoma cells with respect to other healthy cell
lines. The preferential uptake by GBM cells has been
demonstrated in vitro with different approaches, both in static
and in dynamic conditions, with ad hoc developed microfluidic
bioreactors. The resulting Ang-LMNVs could cross a fluidic in
vitro model of the BBB more efficiently than nonfunctionalized
nanovectors, maintaining their ability to selectively target
tumor cells after the BBB crossing. We also aimed at
elucidating the mechanism of action of the drug and, in
particular, of SPIONs stimulated with an appropriate AMF,
showing that the latter induces lysosomal membrane
permeabilization (LMP) with a consequent release of
proteolytic enzymes from the lysosome milieu.20,21 The
combination of nutlin-3a delivery and magnetic stimulation
significantly reduces the viability of GBM cells, inducing cell
apoptosis via different pathways and inhibiting tumor growth.
■ MATERIALS AND METHODS
Lipid-Based Magnetic Nanovector Synthesis. Lipid-based
magnetic nanovectors (LMNVs) were synthesized similarly to a
previous work.17 In brief, 25 mg of 1-stearoyl-rac-glycerol (GMS,
Sigma-Aldrich), 2.5 mg of oleic acid (Sigma-Aldrich), 2.5 mg of 1,2-
dipalmitoyl-rac-glycero-3-phosphocholine (DPPC, Sigma-Aldrich), 2
mg of mPEG-DSPE (5000 Da, Nanocs, Inc.), 2 mg of NHS-PEG-
DSPE (5000 Da, Nanocs, Inc.), and 1 mg of nutlin-3a (Sigma-
Aldrich) were mixed with 84.5 μL of an ethanol solution of SPIONs
(15 wt %, US Research Nanomaterials, Inc.), inside a 6 mL glass vial.
The above mixture was heated at 70 °C to melt the lipids. Then, 3 mL
of a Tween 80 (Sigma-Aldrich) aqueous solution (1.0 wt %) at 70 °C
was added to the lipid mixture, vortexed for 1 min, and sonicated for
20 min (amplitude 90%) using an ultrasonic tip (Fisherbrand Q125
Sonicator). LMNVs were cooled down at 4 °C for 30 min and then
purified by centrifugation (16 000g, 90 min, 4 °C) and redispersed in
Milli-Q water (Millipore) three times. Plain LMNVs were synthesized
as described above, but without adding nultin-3a to the lipid mixture.
Lipid-based nanovectors without SPIONs (LNVs) have been
prepared as required for the NMR characterization, following the
same procedure but without the addition of magnetic nanoparticles.
For functionalization, 100 μL of an angiopep-2 (Selleckchem)
solution in water (1 mg/mL) was added to 1 mL of LMNV dispersion
(6 mg/mL) to have an approximate NHS-PEG-DSPE:angiopep-2
theoretical molar ratio of 1:2. The dispersion was diluted in
phosphate-buffered saline (PBS, Sigma-Aldrich) to optimize the pH
for the reaction between NHS and the amine groups on the peptide.
The solution was left under gentle shaking at 4 °C in the dark for 4 h.
Then, it was washed three times by centrifugation (16 000g, 90 min, 4
°C), and the final pellet was redispersed in 1 mL of Milli-Q water.
For confocal imaging, Ang-LMNVs and LMNVs were labeled with
a fluorescent Vybrant DiO cell-labeling dye (Invitrogen) by
incubating 1 mg of particles with 10 μL of dye for 2 h at 37 °C
and then washing three times by centrifugation (16 000g, 90 min, 4
°C).
Lipid-Based Magnetic Nanovectors Characterization. Trans-
mission electron microscopy (TEM) was performed to analyze
morphology and size of the nanovectors. Before the measurement, the
samples were sonicated for 2 min. A drop of a sample was deposited
on a Cu grid (150 mesh) coated with an ultrathin amorphous carbon
film. After 20 s, the drop was removed with a filter paper and the grid
washed with Milli-Q water. Afterward, a drop of a solution of 1%
uranyl acetate in water was deposited on the grid for 60 s to stain the
sample and to enhance the contrast of the lipid component. Finally,
the drop was removed with a filter paper. Images were acquired with a
JEOL Jem-1011 (Jeol) working at 100 kV on single-tilt sample holder.
Images in bright-field mode were acquired with the same instrument,
following the same sample preparation protocol, but skipping the
staining procedure.
Dynamic light scattering measurements were carried out with a
Zetasizer NanoZS90 (Malvern Instruments Ltd) to determine the
hydrodynamic diameter and the ζ-potential of LMNVs and Ang-
LMNVs at 37 °C. The dispersions, at a concentration of 100 μg/mL
in ultrapure water, were sonicated for 30 s with a Bandelin ultrasonic
probe (8 W) before the measurement. The stability of Ang-LMNVs at
pH 4.5 (0.05 M phosphate buffer) and pH 7.4 (PBS) was evaluated
by diluting a nanoparticle stock solution (15 mg/mL) in the
corresponding buffer up to a final concentration of 100 μg/mL and
measuring the hydrodynamic diameter at different time points (24,
48, 72, and 96 h). The intensity distribution was derived from the
correlogram through CONTIN analysis, whereas the hydrodynamic
diameter and the polydispersity index were obtained from cumulant
analysis.
Thermogravimetric analysis (TGA) was performed with a Q500
analyzer (TA Instruments). Scanning was performed in the
temperature range of 30−600 °C, using a 10 °C/min heating rate.
Cooling was achieved using a 50 mL/min nitrogen flow.
The conjugation of the peptide to the nanoparticles was verified by
1H NMR (Bruker Ascend 400) by monitoring the disappearance of
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the peak related to the NHS group ((C(O)CH2CH2C(O), (4 ×
tfonc)H, δ = 2.6 ppm). Freeze-dried samples were dissolved in CDCl3
(Sigma-Aldrich) prior to the analysis. LNVs were used for this
characterization to avoid the interference between SPIONs and the
magnetic field. 1H NMR spectra were analyzed with Mestrenova.
Sodium dodecyl sulfate−poly(acrylamide) gel electrophoresis
(SDS-PAGE) was performed to quantify the peptide on the
nanovector surface. Each sample (37.5 μL of angiopep-2, LMNVs,
or Ang-LMNVs) at a known concentration was added to 12.5 μL of
Laemmli buffer (BioRad) and heated for 10 min at 95 °C for protein
denaturation. A 4−15% Mini-PROTEAN TGX Precast Protein Gel
(BioRad) was placed in an electrophoresis cell (Mini-PROTEAN
Tetra Cell, BioRad) filled with Tris/Glycine running buffer (BioRad).
The pretreated samples (50 μL) were loaded in each well, in parallel
with a molecular weight marker (PageRuler Plus Prestained Protein
Ladder, Thermo Fisher Scientific). The gel was then run at 100 V for
1 h. Afterward, the gel was stained with Coomassie Blue (for 100 mL
of solution: 0.125 g of brilliant blue R250, 10 mL of glacial acetic acid,
40 mL of water, 50 mL of methanol) for 1 h under gentle agitation.
The gel was then rinsed twice with a destaining solution (10% glacial
acetic acid, 40% H2O, 50% methanol) for 20 min to remove
unspecific staining. Finally, the gel was washed with Milli-Q water.
The bands, corresponding to the peptide, were analyzed for
quantification with ImageJ software. The intensity of the bands
corresponding to Ang-LMNVs was compared to that one of the bands
of the plain peptide.
The presence of three phenylalanine residues in angiopep-2 allows
for its detection with fluorescence spectroscopy by measuring the
characteristic emission intensity at around 300 nm. A Cary Eclipse
fluorescence spectrofluorometer (Agilent Technologies) was used to
measure the emission signal between 270−400 nm, with an excitation
wavelength of 260 nm. The spectra obtained for Ang-LMNVs were
normalized by the nonfunctionalized LMNVs spectra to remove the
background scattering. The intensity at 300 nm of Ang-LMNVs was
compared to a calibration curve obtained with several concentrations
of the free peptide in Milli-Q water.
The presence of angiopep-2 and its amount on the nanovector
surface was also confirmed by bicinchoninic acid assay (BCA) Protein
Kit (Thermo Scientific). Briefly, 25 μL of 8 mg/mL Ang-LMNVs or
LMNVs (used as control) was mixed with 200 μL of working
solution. The samples were then incubated at 37 °C for 30 min, and
the absorbance at 560 nm of 90 μL of the samples was measured in
triplicate with a plate reader (VICTOR X3 plate reader, PerkinElmer).
The amount of peptide conjugated to the nanovectors was calculated
using a calibration curve obtained by performing the BCA assay to
several concentrations (range 0−500 μg/mL) of free angiopep-2 in
water.
The loading and release of nutlin-3a from Ang-LMNVs were
evaluated by high-performance liquid chromatography (HPLC) with
a Shimadzu LC-20AT, using a C-18 column (150 mm × 4.6 mm i.d.,
5 μm particle size). The mobile phase was composed of 80%
methanol (for HPLC, ≥99.9%, Sigma-Aldrich) and 20% H2O (HPLC
Plus, Sigma-Aldrich), pumped in isocratic mode at a flow rate of 1
mL/min. The peak of nutlin-3a was found at a retention time of 4.77
min, and its intensity was monitored by a UV detector at 260 nm.
For the quantification of drug loading, 1 mg of freeze-dried Ang-
LMNVs was dissolved in 400 μL of methanol and heated at 70 °C for
1 h to melt the lipid core. Afterward, 100 μL of cold ultrapure water
was added and the sample was centrifuged at 16 000g for 90 min at 4
°C. The supernatant was collected and measured with HPLC. The
drug loading (%) and the encapsulation efficiency (%) were calculated
using the equations
drug loading (%)
nutlin mass in LMNVs (mg)
total mass of LMNVs (mg)
100= ×
(1)
encapsulation efficiency (%)
nutlin in LMNVs (mg)
added nutlin (mg)
100= ×
(2)
For the release studies, 1 mg of Ang-LMNVs was redispersed in 1 mL
of four different buffers: at pH 7.4 (PBS) to simulate the physiological
environment; at pH 7.4 + 100 μM H2O2 to simulate the physiological
environment in the presence of oxidative stress; at pH 4.5 (0.05 M
phosphate buffer) to simulate the cancer environment; and at pH 4.5
+ 100 μM H2O2 to simulate the cancer environment in the presence
of oxidative stress. The samples were left under agitation at 37 °C. At
each time point (6, 24, 48, 72, and 96 h), the samples were
centrifuged at 16 000 g for 90 min at 4 °C. The supernatants were
collected and analyzed with HPLC, whereas the pellets were
redispersed in their buffers and left under agitation until the following
time point. To study the effect of the application of an alternating
magnetic field (AMF) on the release profile, 1 mg of Ang-LMNVs
dispersed in the corresponding buffers were stimulated for 2 h with a
MagneTherm device (NanoTherics) at an applied magnetic field of
20 mT, using a water-cooled coil of 9 turns and 44 mm inner
diameter, and at a frequency of 753 kHz (for details on the parameters
used for the chronic stimulation of the cells, see the following).
Cellular Uptake Evaluation in Static Conditions. The uptake
of LMNVs and Ang-LMNVs by human glioblastoma U87 MG cells
(ATCC HTB-14) was evaluated in vitro in static conditions. Cells (15
× 103 cells/cm2) were seeded on sterilized glass coverslips and
incubated with high-glucose DMEM (4.5 mg/mL), 10% FBS, 1%
penicillin/streptavidin (P/S), and 1% L-glutamine. U87 MG cells
were subsequently incubated for 6 h at 37 °C with 400 μL of 200 μg/
mL of either Ang-LMNVs or LMNVs (previously labeled with
Vybrant DiO dye) in complete medium.
For confocal acquisition, the cells were washed twice with PBS and
fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich) for 20 min at 4
°C. Then, the cells were incubated with a blocking solution consisting
of goat serum (GS, 10%; EuroClone) and Triton X-100 (1:1000
dilution, Sigma-Aldrich) in PBS for 30 min. The cells were stained
with TRITC-phalloidin (1:200 dilution, Sigma-Aldrich) and Hoechst
33342 (1:1000 dilution, Invitrogen) in PBS for 30 min at 37 °C.
Confocal microscopy acquisitions were performed using a C2s
confocal microscope (Nikon).
Quantitative analysis of the targeting efficiency was performed by
flow cytometry (Cytoflex Beckmann) at the same experimental
conditions. Before the measurements, the cells were washed three
times with PBS, treated with 0.05% trypsin-EDTA, centrifuged, and
resuspended in PBS. The fluorescence of the cells was measured (λex
= 488 nm; λem = 525−540 nm), and the fluorescence intensity of the
nontreated control cells was used as threshold.
Selective Targeting Efficiency in Dynamic Conditions. An ad
hoc fluidic bioreactor was designed and fabricated to test the targeting
efficiency of Ang-LMNVs vs LMNVs. The poly(methyl methacrylate)
(PMMA) bioreactor is composed of six independent chambers
located in three channels; each chamber has been designed to host a
glass coverslip of 0.9 cm2 (see a schematic representation of the fluidic
bioreactor and a schematic representation of cell lines disposition in
Figure S1). Four different cell lines were used to recreate a simplified
in vitro model of the brain environment: neuron-like cells derived
from the SH-SY5Y human neuroblastoma (ATCC CRL-2266),
human primary astrocytes (HA) from cerebral cortex (Innoprot,
P10251), human glioblastoma U87 MG cells (ATCC HTB-14), and
human endothelial hCMEC/D3 cells (Merck Millipore, SCC066).
Concerning SH-SY5Y cell differentiation, 10 × 103 SH-SY5Y cells/
cm2 are seeded on 1.9 cm2 glass coverslips into a 24-well plate with
Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12
(DMEM/F12; Sigma-Aldrich) supplemented with 10% of FBS and
1% P/S. The neural differentiation is induced by replacing the cell
growth medium with differentiation medium: DMEM high-glucose
(4.5 mg/mL), 1% FBS, 10 μM retinoic acid, and 1% P/S for 6 days.
Neuron-like cells derived from differentiation of SH-SY5Y cells will be
referred, for convenience, as SH-SY5Yd throughout the paper. SH-
SY5Y cells were seeded 8 days before the targeting experiment. After
the seeding, the cells were maintained for 2 days in proliferative
conditions, and thereafter switched to differentiation for 6 days. The
other cell lines were seeded 2 days before the experiment, and they
were maintained in proliferative conditions: DMEM high-glucose with
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10% of FBS and 1% P/S for U87 MG and HA, and EndoGRO-MV-
VEGF medium (Merck Millipore) with 5% FBS and 1% P/S for
hCMEC/D3. Two bioreactors were connected in series to a peristaltic
pump (Ibidi fluidic unit), and triplicates of each cell line were placed
along the channels. Vybrant DiO-labeled Ang-LMNVs or LMNVs
suspensions (15 mL, 200 μg/mL) in DMEM high-glucose with
HEPES and 10% FBS were perfused at a speed flow of 2 mL/min for
6 h at 37 °C. After perfusion, the suspension containing the
nanovectors was removed and the cells were washed two times with
PBS, fixed with PFA (4% in PBS for 20 min at 4 °C), left for 30 min
in the blocking solution, and stained with TRITC-phalloidin and
Hoechst 33342, as previously described; confocal laser scanning
microscopy was finally performed and volume analysis of the
nanovectors−cell co-localization (%) was performed using NIS-
Elements software (Nikon), as described in a previous work.18
Blood−Brain Barrier Investigation. To study the ability of
LMNVs and Ang-LMNVs to cross the BBB and their interactions
with the brain microenvironment, another ad hoc developed
bioreactor populated by the above-mentioned four different human
cell cultures was designed. The bioreactor, fabricated in PMMA, is
composed of two chambers. The upper chamber, realized basing on a
previous model,22 mimics the endothelial lumen, and is composed of
a channel 15 mm long, 5 mm large, and 0.5 mm high (Figure S2).
According to this geometry, a flow of 12 mL/min is needed to
reproduce the typical shear stress experienced in brain capillaries (10
dyn/cm2).23 The bottom chamber is 2 mm high with a total surface of
20 mm2, and it is designed to allocate two glass coverslips of 0.9 cm2
each. One of the two glass coverslips was seeded with U87 MG cells
(20 × 103 cm2), while the other was seeded with SH-SY5Yd cells (10
× 103 cells/cm2); both cell types were cultured separately and
inserted in the BBB setup 1 day before the experiment. The top and
bottom chambers are separated by a poly(ethylene terephthalate)
(PET) transparent porous membrane with pores of 3 μm. The upper
surface of the porous membrane was seeded with human endothelial
cells hCMEC/D3 (5 × 104 cells/cm2) in EndoGRO-MV-VEGF
medium (Merck Millipore) with 5% FBS and 1% P/S, whereas the
other side was seeded with HA (8 × 103 cells/cm2) 3 days after
hCMEC/D3 seeding. Experiments were performed after 5 days, when
the endothelial cells formed a monolayer.
The quality of the BBB was assessed by measuring the
transendothelial electrical resistance (TEER) with a Millipore Millicell
ERS-2 Volt-Ohmmeter and the permeability to a 200 μg/mL
rhodamine B-dextran (70 kDa, Invitrogen) solution in complete
medium, as previously described in other works.24
Nanovector/Cell Interactions. The uptake mechanism of Ang-
LMNVs by U87 MG cells was investigated by confocal fluorescence
microscopy (C2 system Nikon), focusing on the pinocytosis pathway
and on the clathrin- and caveolin-mediated endocytosis.
Pinocytosis was studied using the Cascade Blue hydrazide
fluorescent dye (Invitrogen). U87 MG cells (15 × 103 cells/cm2)
were seeded in WillCo dishes. After 1 day, the cells were incubated for
24 h with 200 μL of phenol red-free HEPES-supplemented complete
medium with 300 μM of Cascade Blue hydrazide fluorescent dye and
with 200 μg/mL of Vybrant DiO-labeled Ang-LMNVs. After 24 and
72 h, the cells were washed three times and refilled with fresh phenol
red-free HEPES-supplemented complete medium. Confocal images
were acquired immediately, and a co-localization analysis (Pearson’s
correlation coefficient) between nanovectors and pinosomes was
performed by NIS-Elements software.
Caveolin-1 and clathrin-mediated internalization pathways were
studied by immunofluorescence. Vybrant DiO-labeled Ang-LMNVs
(200 μL, 200 μg/mL) in complete medium were administered for 24
and 72 h to U87 MG cells seeded in WillCo dishes, as previously
reported. The cells were then fixed with 4% PFA for 20 min at 4 °C,
washed with PBS, and incubated with a blocking solution for 30 min.
The samples were then incubated at 37 °C with anti-caveolin-1
(1:150; Abcam) primary antibody or anti-clathrin primary antibody
(1:150; Abcam) in PBS with 10% GS for 2 h. After three washes with
10% GS in PBS, the samples were stained for 1 h with Alexa-Fluor-
488 secondary antibody (1:250 dilution; Millipore), TRITC-
phalloidin (1:200; Sigma-Aldrich), and Hoechst 33342 (1:1000;
Invitrogen). Confocal fluorescence microscopy and co-localization
analysis were performed as previously described.
Ang-LMNV uptake in lysosomes and late endosomes was assessed
by confocal fluorescence microscopy. U87 MG cells (15 × 103 cells/
cm2) were seeded in WillCo Petri dishes and subsequently incubated
with 200 μL of 200 μg/mL of Vybrant DiO-labeled Ang-LMNVs in
phenol red-free HEPES-supplemented DMEM high-glucose with 10%
FBS for 24 and 72 h. The samples were washed twice with PBS and
treated with the acidotropic LysoTracker Deep Red dye (1:2000
dilution, Invitrogen) in high-glucose phenol red-free HEPES-
supplemented complete medium. After 30 min, the cells were washed
and stained with Hoechst 33342 (1:1000 dilution, Invitrogen) for 15
min at 37 °C. Confocal fluorescence microscopy and co-localization
analysis were performed as previously described.
Cell Viability Assay. Cell viability was assessed using the WST-1
assay (Roche). U87 MG (15 × 103 cells/cm2) were seeded (in
triplicate for each experimental class) in 24-well plates, and their
viability was evaluated upon treatment with different concentrations
of free nutlin-3a in DMSO (1, 3, 5, and 10 μM), Ang-LMNVs (109,
325, 544, and 1089 μg/mL), and Nut-Ang-LMNVs (109, 325, 544,
and 1089 μg/mL corresponding to 1, 3, 5, and 10 μM of nutlin-3a)
for 24 and 72 h. Cultures were incubated with 300 μL of phenol red-
free complete medium with the WST-1 reagent (1:20 dilution) for 30
min at 37 °C. Thereafter, absorbance at 450 nm was measured using a
PerkinElmer Victor X3 UV−Vis spectrophotometer. The values were
expressed as % with respect to untreated controls.
The effect of Nut-Ang-LMNVs on different cell lines was
investigated with the same fluidic bioreactor setup used for the
targeting efficiency experiments, and 325 μg/mL of Nut-Ang-LMNVs
(corresponding to 3 μM of nutlin-3a) were perfused. U87 MG cells,
hCMEC/D3, SH-SY5Yd, and HA were placed in the fluidic
bioreactor, as previously described. After 6 h, the perfusion was
stopped, the cells were washed three times with PBS and placed in an
incubator at 37 °C for 72 h. The cells were then incubated with 300
μL of phenol red-free complete medium with the WST-1 reagent for
20 min in the case of U87 MG cells, and for 90 min in the case of
hCMEC/D3, SH-SY5Yd, and HA because of different metabolic rates.
The absorbance at 450 nm was thereafter measured as described
above. The toxic effect of free nutlin-3a (3, 5, and 10 μM in DMSO)
on hCMEC/D3 (15 × 103 cells/cm2), SH-SY5Yd (10 × 10
3 cells/
cm2), and HA (10 × 103 cells/cm2) at 72 h was also analyzed by the
WST-1 assay, using the same protocol.
Finally, the effect of the AMF stimulation was studied as follows.
U87 MG cells (15 × 103 cells/cm2, seeded at the center of WillCo
dishes) were incubated with 325 μg/mL of Ang-LMNVs or Nut-Ang-
LMNVs (corresponding to 3 μM encapsulated drug) or with 3 μM
free nutlin-3a in DMSO for 48 h. Thereafter, cultures were exposed to
AMF for 2 h/day with a MagneTherm device (NanoTherics) at an
applied magnetic field of 20 mT, using a water-cooled coil of 9 turns
and 44 mm inner diameter, and a frequency of 753 kHz, for 3 days.
Control samples were left in the incubator without undergoing AMF
stimulation. After the AMF chronic stimulation, the cell viability of
each sample was assessed by WST-1. The same experimental protocol
was also used to perform “rescue of viability” experiments: briefly, at
the end of the 3-day AMF chronic stimulation, the cells were placed in
the incubator for further 72 h before performing viability (WST-1)
investigations.
Lysosome Permeabilization Investigation. To study the effect
of the nanovector-mediated AMF stimulation on lysosomes, U87 MG
cells were seeded (15 × 103 cells/cm2) in WillCo dishes and
incubated for 72 h with 325 μg/mL of Vybrant DiO-labeled Ang-
LMNVs in phenol red-free HEPES-supplemented complete medium.
After 72 h, the cells were stained with LysoTracker Deep Red dye and
Hoechst 33342, as previously described, and stimulated for 2 h with
the MagneTherm device (NanoTherics) using a Live Cell AMF
exposure system (NanoTherics) at 16 mT and 753 kHz, a setup
allowing for a live confocal acquisition during the stimulation time.
Confocal time-lapse imaging (C2 system, Nikon) was carried out with
a perfect focus system (Nikon). The heating of the objective during
ACS Applied Materials & Interfaces www.acsami.org Research Article
https://dx.doi.org/10.1021/acsami.0c05556
ACS Appl. Mater. Interfaces 2020, 12, 29037−29055
29040
the AMF stimulus was avoided by an automatic lowering of the
microscope revolver after each acquisition (every 1 min) exploiting
the escape function (NIS-Elements software); the revolver was then
lifted, and the perfect focus function was activated just before the
acquisitions.
The release of proteolytic enzymes from lysosomes was monitored
by immunostaining of cathepsin B. Vybrant DiO-labeled Ang-LMNVs
(325 μg/mL) in HEPES-supplemented complete medium were
administrated to U87 MG cells previously seeded (15 × 103 cells/
cm2) in WillCo dishes. After 48 h of incubation, the cells were
stimulated with an AMF. The samples (control and Ang-LMNV-
pretreated cells) were fixed immediately after the AMF treatment with
pure methanol at −20 °C for 15 min. After three times washing with
PBS and a step with the blocking solution, the cells were incubated
with anti-cathepsin B antibody (1:100, Abcam) at 37 °C for 2 h. After
three washing steps, TRITC anti-rabbit secondary antibody (1:250,
Invitrogen) was added to the samples for 1 h at 37 °C. Images were
acquired with a confocal microscope.
Heat Shock Protein 70 Expression. Immunofluorescence
experiments against heat shock protein 70 (Hsp70) were performed
to evaluate an increase of its expression as a consequence of the
treatment with Ang-LMNVs + AMF stimulus. U87 MG cells were
seeded (15 × 103 cells/cm2) at the center of WillCo dishes (1 cm2
total area) and then incubated with 325 μg/mL of Ang-LMNVs in
HEPES-supplemented complete medium for 2 days before being
stimulated for 2 h with the AMF, as previously described. Negative
controls and positive controls were also performed; in particular,
negative controls were represented by cultures without any treatment,
while positive controls were placed for 1 and 2 h in an incubator at 42
°C. This temperature was chosen since it is the typical temperature
achieved during hyperthermia treatments. After the stimulation, the
samples were placed at 37 °C for a further hour in the incubator.
Afterward, the samples were fixed with 4% of PFA at 4 °C.
Immunostaining was performed with anti-Hsp70 antibody (1:50,
Abcam) for 2 h at 37 °C; after three washing steps, FITC-labeled
secondary anti-rabbit antibody (1:250, Invitrogen) was added and
incubated for 1 h. Nuclei staining was performed with Hoechst 33342
(1:1000 dilution, Invitrogen) for 20 min; images were acquired with
the confocal microscope.
Evaluation of Apoptotic Effects and Caspase-9 Activation.
The expression of p53 and Ki-67 markers was investigated by
immunofluorescence to evaluate the effects on apoptosis (p53) and
on cell proliferation (Ki-67) after the treatment with Ang-LMNVs or
Nut-Ang-LMNVs (with or without AMF). The concentrations used
for this experiment were 325 μg/mL of Ang-LMNVs or Nut-Ang-
LMNVs (corresponding to 3 μM encapsulated drug) and 3 μM free
nutlin-3a in DMSO. The AMF stimulation protocol consisted of 2 h/
day stimulation in DMEM high-glucose complete medium and
HEPES with a MagneTherm device (NanoTherics) at an applied
magnetic field of 20 mT, using a water-cooled coil of 9 turns and 44
mm inner diameter, and a frequency of 753 kHz, for 3 days. The same
experimental protocol was also used to perform rescue experiments, as
previously described for cell viability assays.
Concerning immunofluorescence, after fixation cells were incu-
bated for 30 min with the blocking solution. Thereafter, cultures were
incubated with primary rabbit anti-Ki-67 antibody (1:150 dilution,
Figure 1. (A, B) Representative TEM images of Ang-LMNVs at different magnifications. (C) Size distribution derived from TEM images. (D)
Intensity distribution (%) as a function of the hydrodynamic diameter (nm) for LMNVs (black) and Ang-LMNVs (red). (E) ζ-Potential (mV)
distribution of LMNVs (black) and Ang-LMNVs (red). (F) TGA/DTG thermogram of Ang-LMNVs, showing the weight loss (black) and its
derivative (blue) at increasing temperatures. (G) SDS-PAGE of angiopep-2, bare LMNVs, and Ang-LMNVs. (H) Fluorescence spectroscopy of
angiopep-2 (black) and Ang-LMNVs (red).
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Millipore) and a primary mouse anti-p53 antibody (1:100 dilution,
Abcam) for 2 h at 37 °C. Afterward, the cells were incubated for 1 h
with an FITC-conjugated secondary anti-rabbit antibody (1:250
dilution, for Ki-67 staining, Millipore), and, after a washing step, with
a TRITC-conjugated secondary anti-mouse antibody (1:250 dilution,
for p53 staining, Millipore). Finally, 20 min incubation with Hoechst
33342 in PBS (1:1000 dilution, Invitrogen) for nucleus counter-
staining was performed. Imaging was carried out with a C2s confocal
microscope (Nikon); NIS-Elements software (Nikon) was used for
the analysis of the p53 and Ki-67 positive nuclei.
CaspGLOW Fluorescein Active Caspase Staining Kit (BioVision)
was used to investigate the activation of caspase-9, and thus the
initiation of the apoptosis mediated by this pathway, in cells treated
with Ang-LMNVs, Nut-Ang-LMNVs, or plain nutlin-3a, with or
without the AMF stimulus. U87 MG cells were seeded (15 × 103
cells/cm2) in WillCo dishes and then incubated for 48 h with a 325
μg/mL dispersion of either Ang-LMNVs or Nut-Ang-LMNVs, or with
nutlin-3a 3 μM (corresponding to the dose loaded in 325 μg/mL of
Nut-Ang-LMNVs). Half of the samples underwent AMF stimulation
for 2 h at 37 °C. After the treatments, cultures were left for 1 h in the
incubator without any stimulus. The cell medium was then replaced
with a working solution of caspase-9 fluorescent dye (33 μL stock
solution was added in 167 μL of complete medium), and the samples
were incubated for 1 h. Afterward, the cells were washed three times
with the specific washing solution provided by the kit. Fluorescence
imaging was performed with a C2s confocal microscope (Nikon). The
same experimental classes were also analyzed with flow cytometry
(Cytoflex Beckmann) at λex = 488 nm and λem = 525−540 nm, after
cell detachment with a 0.05% Trypsin-EDTA and resuspension in
PBS upon centrifugation.
Statistical Analysis. The statistical analysis was performed by t-
test with Microsoft Excel or OriginLab softwares.
■ RESULTS AND DISCUSSION
Physicochemical Characterization of the Nanovec-
tors. LMNVs were synthesized with a hot sonication
procedure, as previously described,17 and functionalized with
angiopep-2 owing to the formation of an amide bond between
one of the primary amine groups on the peptide and the NHS
reactive group at the end of the NHS-PEG-DSPE.
TEM image shows that Ang-LMNVs present a spherical
morphology with a diameter distribution centered around 20 ±
5 nm, being only a few particles larger than 100 nm (Figure
1A−C). The black spots in the particles could represent small
SPION aggregates encapsulated in the lipid core. However, the
uranyl acetate staining could create artifacts, leading to
misinterpretation. For this reason, Ang-LMNVs were also
analyzed without staining, for comparison. Due to difficulties
in identifying lipid nanoparticles without staining, only the
large aggregates, probably formed during the drying process,
can be observed; nevertheless, it is evident that SPIONs are
well encapsulated within Ang-LMNVs (Figure S3). This
evidence is supported by the results reported in a previous
work.17
Dynamic light scattering measurements (Figure 1D) high-
light that the peptide conjugation does not affect the final
hydrodynamic size of the nanovectors. In fact, LMNVs have an
average hydrodynamic diameter of 169 ± 4 nm with a
polydispersity index of 0.24 ± 0.03, whereas Ang-LMNVs have
a hydrodynamic diameter of 179 ± 3 nm and a polydispersity
index of 0.12 ± 0.01. The small increase in size (around 10
nm), confirmed by the little displacement of the maximum of
the size distribution in Figure 1D, could be due to the presence
of the peptide that is orientated toward the solvent rather than
being adsorbed flat on the surface.
The differences in size detected by DLS and TEM are
mainly due to the differences between the two analytical
methods. DLS measures the hydrodynamic sizethe size of
the particle plus its solvation sphere, its polymer shell and the
stabilizergiving rise to larger sizes.25 Moreover, DLS
intensity distribution is much more sensitive toward larger
aggregates than small ones.26 Finally, some of the small
particles observed by TEM could be perceived as agglomerates
of hundreds of nanometers in DLS, giving rise to misinter-
pretation of the particles mean size. Nevertheless, DLS is a
valuable quick tool to establish the behavior of nanoparticles in
solution.
The ζ-potential of Ang-LMNVs (−32.0 ± 0.6 mV) is only
slightly more positive than that one of LMNVs (−39.0 ± 0.8
mV) (Figure 1E). The decrease of the absolute value of ζ-
potential is due to the partial screening of LMNV surface
charge by the peptide; nevertheless, the ζ-potential is still
within the colloidal stability limit (|30| mV),27 preventing the
aggregation of Ang-LMNVs. Moreover, the presence of PEG
and peptide chains on the particle surface imparts further steric
stability to the system.
The stability of Ang-LMNVs in terms of hydrodynamic
diameter and polydispersity index (PdI) was evaluated at
different pH values, in particular at pH 7.4 to mimic the
physiological conditions and at pH 4.5 to simulate the
environment of tumor and/or acidic organelles. As shown in
Figure S4, the Ang-LMNV diameter and PdI are quite stable
until 96 h (the time window used for release studies and AMF
chronic treatments), with just a moderate increment in size at
pH 4.5 within the first 48 h (from 241 ± 6 nm at 24 h to 330 ±
35 nm at 48 h).
To quantify the fraction of SPIONs composing the
nanovectors, TGA was performed on Ang-LMNVs (Figure
1F). The weight loss (in black) and the corresponding
derivative weight curve (in blue) show that the total weight of
the system decreases as the temperature increases due to the
decomposition of the organic components. The weight loss
occurs in several steps since the different lipids and polymers
have different decomposition temperatures, as evidenced by
the derivative thermogravimetry (DTG) curve in Figure 1F.
The initial weight loss between 50 and 100 °C can be ascribed
to the evaporation of water molecules on the nanovector
surface. The first peak in the DTG graph can be attributed to
the decomposition of oleic acid as well as to the initial
decomposition of lipids, such as GMS and DPPC.28,29 DPPC,
in particular, is reported to degrade in differential steps, with a
maximum weight loss at around 288 °C (the third peak).29
The same applies for the DSPE component of mPEG-DSPE.30
Therefore, the peaks between 185 and 288 °C can be
attributed to the degradation of the lipid component of
LMNVs. The final peak at 394 °C is correlated to the
decomposition of the PEG component in mPEG-DSPE.31 At
the end of the heating program (400 °C), the remaining final
mass is that one of the SPIONs since they do no degrade at
such temperatures, and it corresponds to a percentage of
SPIONs encapsulated in Ang-LMNVs of about 70% of the
total weight of the nanovectors.
The success of the peptide conjugation was first assessed by
1H NMR (Figure S5). The functionalization can be monitored
by following the disappearance of the peak related to the NHS
group on the NHS-PEG-DSPE. The presence of SPIONs in
the nanovector would strongly affect the NMR spectra, due to
the interferences between SPIONs and magnetic fields:32 for
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this reason, we decided to perform NMR analysis only on lipid
nanovectors (LNVs) without SPIONs. The synthesis and
conjugation procedure is exactly the same as for the LMNVs.
Since SPIONs are encapsulated inside the core of Ang-
LMNVs, there is no reason to believe that their absence would
affect the conjugation reaction that takes place only on the
nanovector surface. Therefore, we can safely assume that the
results obtained with Ang-LNVs are the same for Ang-LMNVs.
The spectra in Figure S5 show that LNVs (before
functionalization) present the typical peak arising from the 2
protons on the NHS molecule at δ = 2.66 ppm (red curve).33
During the functionalization, the NHS ester-activated PEG-
DSPE reacts with the primary amines on the peptide chain to
form stable amide bonds, with consequent release of the NHS.
Therefore, the loss of the peak at 2.66 ppm from the 1H NMR
spectra of Ang-LMNVs suggests that the reaction was
successful (Figure S5, black curve).
To quantify the amount of peptide on the nanovectors, we
exploited SDS-PAGE with Coomassie staining to highlight the
presence of the peptide in the sample (Figure 1G). LMNVs do
not give rise to a band, as expected, whereas Ang-LMNVs
display a blue band due to the peptide. Comparing the
intensity of the band of the plain peptide with those of Ang-
LMNVs, the amount of peptide conjugated on Ang-LMNVs
was found to be 3.0 ± 0.4 wt %. To validate the SDS-PAGE
results, Ang-LMNVs were also analyzed by fluorescence
spectroscopy (Figure 1H). The peptide shows an emission
with a maximum at around 300 nm, proportional to its
concentration, when excited at 260 nm. Fluorescence spec-
troscopy measurements show that the amount of peptide in
Ang-LMNVs is estimated to be around 2.0 ± 0.5 wt %, in line
with the SDS-PAGE quantification. Finally, the presence of the
peptide on Ang-LMNVs was also confirmed by a BCA assay,
and quantified to be about 1.1 ± 0.8 wt %. Combining all data
obtained with complementary approaches, and considering a
diameter of the nanovector of 20 nm (from TEM), the number
of angiopep-2 molecules on each Ang-LMNVs would be
around 86−108, with a peptide surface density of 0.07−0.08
ligand/nm2. This value is in the same order of magnitude of
other functionalized nanoparticles.18,34
The magnetic properties of LMNVs were already charac-
terized in a previous work;17 in particular, LMNVs possess a
saturation magnetization of 25 emu/g, with no coercivity at the
working temperature. LMNVs (5.4 mg/mL) were shown to be
able to increase the temperature of the medium from 37 to 43
°C in 10 min of stimulation (20 mT and 752.11 kHz).17,18 It
has been also shown that the temperature of a 2D culture of
GBM cells, pretreated with LMNVs (167 μg/mL) and
stimulated for 2 h with an AMF (16 mT and 753 kHz), was
able to reach a plateau of 41 °C after 40 min of stimulation.18
The thermal isoeffective dose (TID) corresponding to this
kind of treatment is about 5 CEM43, which is the “cumulative
equivalent minutes at 43 °C”.35,36 The TID, jointly to the
correlated value expressed in CEM43 units, is commonly used
to normalize different time−temperature exposure protocols as
equivalent exposure time at 43 °C, chosen as a reference
temperature; in this way, different thermal treatments can be
directly compared.35
Drug Loading and Release Studies. Ang-LMNVs were
loaded with the drug nutlin-3a to obtain Nut-Ang-LMNVs,
with a drug loading of 0.5 ± 0.1 wt % and encapsulation
efficiency of 10.6 ± 0.8%. The nutlin-3a release profile was
studied in different conditions: pH 7.4, to simulate
physiological conditions; pH 4.5, to recreate the tumor and/
or the acidic organelles microenvironments; and pH 7.4 and
pH 4.5 with 100 μM H2O2, to mimic a situation of oxidative
stress. All of the four conditions were also investigated in the
presence of the AMF stimulus (2 h stimulation at an applied
magnetic field of 20 mT, using a water-cooled coil of 9 turns
and 44 mm inner diameter, and a frequency of 753 kHz). As
shown in Figure 2, we have a relatively quick release within the
first 24 h, followed by a continuous slower release at longer
times, for all of the considered conditions. Figure 2A,B also
shows that the release of nutlin-3a is higher in acidic
conditions (49 ± 1% of drug released at 96 h), compared to
physiological pH values (37 ± 2% at 96 h). This allows
predicting that the drug will be more efficiently released within
the tumor environment and/or inside acidic organelles, such as
lysosomes. The presence of H2O2 does not have a significant
effect on the cumulative release of nutlin-3a at pH 7.4, but it
seems to slow down the release at pH 4.5. The application of
the AMF does not affect the drug release at pH 7.4, whereas it
seems to have a slight effect at pH 4.5, where the AMF
stimulus increases the amount of nutlin-3a released of about
4% (Figure 2A).
Similar release profiles of nutlin-3a were already observed for
other lipid-based nanosystems.22 The release mechanism of a
drug from nanoparticles depends on several factors, such as the
interactions between the drug and the nanoparticle compo-
nents, the morphology and surface properties of the nano-
particle, the solubility of the drug in different media, and the
location of the drug in the nanoparticle.37 For instance, a rapid
Figure 2. Cumulative release (%) of nutlin-3a from Nut-Ang-LMNVs in different conditions: (A) pH 4.5 (black circles), pH 4.5 + 100 μM H2O2
(red triangles), pH 4.5 + AMF (green upside down triangles), pH 4.5 + 100 μM H2O2 + AMF (blue diamonds). (B) pH 7.4 (black circles), pH 7.4
+ 100 μM H2O2 (red triangles), pH 7.4 + AMF (full green upside down triangles), pH 7.4 + 100 μM H2O2 + AMF (blue diamonds).
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release at short times could be ascribed to the diffusion of the
drug molecules that are localized in the vicinity of the
nanoparticle surface, whereas the other molecules in the
nanoparticle core diffuse more slowly and at longer times.37
Moreover, the physicochemical properties of the drug, such as
its solubility and partition coefficient between lipid and
aqueous phase, can play a crucial role in the release kinetics,
and accounts for the main differences observed in the release
mechanisms from the same nanoparticles.37,38
Nanovector Targeting Efficiency. The uptake of the
nanovectors by U87 MG cells was first assessed in standard
static conditions. Figure 3A shows that the presence of
angiopep-2 on the surface of the nanovectors increases their
uptake by 1.6 times with respect to bare LMNVs, as
highlighted by flow cytometry analysis, and these results are
in good agreement with the confocal microscopy analysis.
(Figure 3B).
The ability of Ang-LMNVs to preferentially target U87 MG
cells was further evaluated in dynamic conditions using a
bioreactor (Figure S1), where different cell lines were exposed
to a cell medium flow loaded with Ang-LMNVs. The cell lines
used for this experiment were HA, hCMEC/D3, SH-SY5Yd,
and U87 MG cells, as they represent a good in vitro model of
the brain cancer microenvironment. The bioreactor was
perfused with a 200 μg/mL dispersion of LMNVs or Ang-
LMNVs, previously labeled with Vybrant DiO, for 6 h.
Confocal acquisitions show an increased uptake of Ang-
LMNVs by U87 MG cells with respect to plain LMNVs (46.3
± 13.8 vs 1.7 ± 1.4% p < 0.05), confirming the results obtained
in static conditions (Figure 4A,B). More interestingly, Ang-
LMNVs own the evident ability to preferentially target U87
MG cells over the other cell lines, as shown by the confocal
acquisitions; conversely, LMNVs are evenly internalized (and
at a qualitative lower extent) by all of the four different
cultures. These data confirm as angiopep-2 functionalization
Figure 3. (A) Flow cytometry on U87 MG cells after 6 h treatment with LMNVs or Ang-LMNVs (labeled with Vybrant DiO dye) in static
conditions (*p < 0.05). (B) Confocal imaging showing the uptake of LMNVs and Ang-LMNVs (in red) by U87 MG cells after 6 h of treatment in
static conditions.
Figure 4. (A) Confocal imaging showing the uptake of LMNVs and
Ang-LMNVs (in green) on different cell lines (HA, hCMEC/D3, SH-
SY5Yd, U87 MG) after 6 h of treatment in dynamic conditions. (B)
Quantitative analysis showing the nanovectors−cell co-localization
(*p < 0.05).
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represents a successful strategy to promote cancer cell active
targeting.
In Vitro BBB Crossing Experiments. As already
mentioned, angiopep-2 binds to LRP1, which is also expressed
on endothelial cells; it was therefore supposed its active role in
promoting a receptor-mediated transcytosis that fosters the
BBB crossing of the nanovectors.13 The efficiency of Ang-
LMNVs to pass through a BBB model was evaluated using an
in vitro dynamic bioreactor. In vitro models represent an
essential step in the characterization of a new therapeutic
approach, in particular in case of the necessity of BBB crossing,
as they give important hints about the estimation of the
passage of a new therapeutic platform.39 Moreover, a good in
vitro model made with human cells can give more accurate
information compared to in vivo models relying on tumor
xenograft on immunosuppressed mice or in genetically
engineered mouse models that lack good reproducibility,
especially for brain cancer applications.40
In our model, we exploited a co-culture of hCMEC/D3 cells
with human astrocytes, to mimic the BBB, and a co-culture of
glioblastoma cells and SH-SY5Yd cells, to mimic the brain
cancer microenvironment (Figure S2). The presence of a flow
is a key element for obtaining a system successfully
recapitulating the physiological conditions, as it has been
demonstrated that the typical BBB phenotype, including the
development of tight junctions and the expression of proteins
like ZO-1, claudin-5, or VE-cadherin, can develop just in the
presence of shear stress.39 The lack of this physical cue in static
models may lead to a higher permeability, giving rise to an
overestimation of drug or nanoparticles crossing the BBB
model.39 Moreover, co-culture with astrocytes has also been
shown to stimulate the development of a good BBB phenotype
and it also favors the expression of transport proteins such as
P-gp and Glut-1, which regulate the molecular transport across
the BBB.39,41 Endothelial cells usually lose these functions after
prolonged in vitro culturing,42 but they can be easily
reactivated under flow and when co-cultured with astrocytes.41
It has been also speculated that shear stress may favor the
expression of cell membrane-bound receptors, such as cell
adhesion molecules and low-density lipoproteins, that activate
receptor-mediated transcytosis.24 On the other hand, fluid
shear stress may work against nanoparticles avidity, reducing
their efficiency to be internalized by endothelial cells.24 These
considerations highlight the importance of using dynamic
models to study the BBB crossing over more simplistic static
models.
Experiments were performed using two bioreactors placed in
series: one just with medium in the lower chamber to quantify
the nanovector passage and the other seeded with U87 MG
cells and neuron-like cells (SH-SY5Yd) in the lower chamber,
to assess whether the targeting abilities of Ang-LMNVs are
preserved upon BBB crossing. A typical barrier used for these
experiments is shown in Figure 5A. The BBB model presents a
TEER of 70.05 ± 4.25 Ω·cm2, whereas the permeability to
rhodamine B-dextran 70 kDa is around 0.34 × 10−6 cm/s,
similarly to other BBB models with hCMEC/D3 cells.43 At the
end of the BBB crossing experiment, the concentration of
LMNVs in the lower chamber was 104.8 ± 1.5 μg/mL,
whereas that one of Ang-LMNVs was about 124.4 ± 4.5 μg/
mL (16.7% more with respect to bare LMNVs, p < 0.05).
Upon BBB crossing, both LMNVs and Ang-LMNVs interact
with the cells seeded in the lower compartment; however, Ang-
LMNVs are selectively internalized by U87 MG cells, with
minimal interaction with SH-SY5Yd cells (Figure 5B,C).
Moreover, the functionalization increases the internalization
extent of the nanovectors in U87 MG cells by almost 20 times
Figure 5. (A) Confocal imaging of a typical barrier formed by hCMEC/D3 and HA, with a scheme of the BBB setup. (B) Uptake of Vybrant DiO-
labeled LMNVs and Ang-LMNVs (in green) by different cell lines (SH-SY5Yd and U87 MG) after BBB crossing. (C) Quantitative analysis showing
the nanovectors−cell co-localization (*p < 0.05).
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with respect to the bare LMNVs (42.7 ± 15.2% of Ang-
LMNVs−cell co-localization, as opposed to 2.0 ± 0.3% for
LMNVs, p < 0.05). Both Ang-LMNVs and LMNVs are
minimally internalized by SH-SY5Yd (2.1 ± 0.9 and 1.6 ± 0.9%
of nanovectors−cell co-localization, respectively). This is in
good agreement with the targeting efficiency results previously
described. These findings not only suggest that Ang-LMNVs
are able to favor the passage of nanoparticles through the BBB,
but also that the interaction with endothelial cells and
astrocytes does not interfere with the targeting abilities of
the nanovectors, which is retained upon the BBB crossing. It
has been previously shown that ligands targeting the LRP1
receptor on the endothelial cells are able to induce receptor-
mediated transcytosis, a process that allows the nanoparticles
to be quickly transported into dedicated vesicles from one side
to the other side of the cells, without being degraded.44
Given the good results obtained in terms of targeting
efficiency and BBB crossing, the following experiments are
reported just for Ang-LMNVs.
Ang-LMNV Internalization Pathway. The internalization
pathway of Ang-LMNVs in U87 MG cells was studied by
investigating markers expressed in caveolae (caveolin-1) and in
clathrin-coated vesicles (clathrin) (Figure 6A), and with
pinosomes staining with Cascade Blue (Figure 6B). Confocal
imaging shows that the nanovectors can enter into the cells
through different pathways. The analysis of the Pearson’s
correlation coefficients (P, Figure 6C) revealed that after 24 h
of incubation, the internalization mediated by caveolae seems
to be prevalent with respect to the other pathways (P = 0.35 ±
0.07 for caveolae, P = 0.19 ± 0.09 for clathrin-coated vesicles,
and P = 0.16 ± 0.07 for pinosomes). At 72 h, both caveolae
and clathrin-coated vesicles mediated internalization decreases,
whereas uptake by pinosomes remains constant (P = 0.04 ±
0.02 for caveolae, P = 0.09 ± 0.02 for clathrin-coated vesicles,
and P = 0.15 ± 0.02 for pinosomes). Receptor-mediated
endocytosis generally occurs via clathrin-coated vesicles and, in
some cases, via caveolae.45,46 LRP1 has been shown to be
present in clathrin-coated vesicles as well as in caveolae, and, in
particular, this receptor seems to be mainly located within the
lipid raft microdomains of the cell membrane.47,48 Therefore,
LRP1-mediated endocytosis through caveolae or clathrin-
coated vesicles takes place only within the first 24 h from the
administration of Ang-LMNVs. At longer times, when most of
the material has been internalized by the cells, pinocytosis
prevails.
Figure 6. Confocal analysis of the internalization of Vybrant DiO-labeled Ang-LMNVs in U87 MG cells mediated by caveolae and clathrin-coated
vesicles (A) or pinosomes (B) at 24 and 72 h. (C) Quantitative evaluation of co-localization (through Pearson’s correlation coefficient) at 24 and
72 h.
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To evaluate the intracellular fate of Ang-LMNVs, we
analyzed the co-localization with lysosomes of U87 MG cells
at different times (Figure 7A,B). At both 24 and 72 h, a
fraction of Ang-LMNVs is localized within lysosomes (P = 0.25
± 0.08 at 24 h and P = 0.26 ± 0.04 at 72 h). The co-
localization is partial: although many lysosomes contain Ang-
LMNVs (see also zoomed areas (i) and (ii) reported in Figure
7A), several Ang-LMNVs are located also out of the organelles.
In this regard, we have to consider that the co-localization
analysis has been carried out considering all of the Ang-
LMNVs associated with the cells (e.g., also those associated
with the plasma membranes), and this explains the relatively
low P index. The release studies showed that the nutlin-3a
release from the nanovectors is quicker at pH 4.5, which
corresponds to the typical pH values inside lysosomes (ca.
4.5−5.0). This pH-dependent behavior allows for a more
efficient release of the drug in acidic environment, such as the
tumor milieu and lysosomes, with a lower impact on healthy
tissues.49,50
Nanovectors as Drug-Delivery Systems. The cytotox-
icity of free nutlin-3a, Ang-LMNVs, and Nut-Ang-LMNVs was
tested on U87 MG cells at different concentrations and for 24
and 72 h of treatment (Figure 8A). Ang-LMNVs affect U87
MG cells only at the highest tested concentration (1089 μg/
mL); nutlin-3a does not have a significant effect at 24 h,
whereas, after 72 h, the highest concentration (10 μM) is able
to induce a decrease of the cell metabolic activity (down to 27
± 2%, p < 0.05), in agreement with previous studies.15,51 On
the other hand, when treated with Nut-Ang-LMNVs, the
viability of U87 MG cells is significantly reduced already at
lower concentrations. For instance, at 72 h, the viability of U87
MG cells treated with 325 μg/mL of Nut-Ang-LMNVs
(corresponding to 3 μM of encapsulated drug) is reduced to
almost 33 ± 3% (p < 0.05), whereas the plain drug at the same
concentration has no effect (Figure 8A). For this reason, we
chose this concentration as the optimal condition for the
treatment of U87 MG cells and for further characterizations
concerning the mechanism of action of the nanovectors. The
increased efficiency of the drug when loaded into nanoparticles
is probably due to the fact that nanoparticle-mediated delivery
allows reaching a higher concentration of drug inside the cells,
which cannot be obtained by the drug alone due to its very low
solubility in aqueous environments.
Another important point we addressed is the toxicity of
nutlin-3a and of Nut-Ang-LMNVs toward the other cell lines.
The effect of Nut-Ang-LMNVs was thus tested on four
different cell lines (U87 MG, HA, hCMEC/D3, and SH-SY5Yd
cells) in dynamic conditions. Cells were perfused with a
dispersion of 325 μg/mL of Nut-Ang-LMNVs that corre-
sponds to 3 μM of drug. After 6 h, the cells were rinsed with
PBS and left with fresh media for further 72 h to allow the
nanovectors to be internalized and the drug to carry out its
action. As reported in Figure 8B, the effect of Nut-Ang-
LMNVs is significant just for U87 MG cells (cell viability
decreased to 52 ± 11% with respect to control cells, p < 0.05).
Interestingly, drug-loaded nanovectors did not induce a
decrease in cell viability in all of the other cell lines. For
comparison, the free drug was tested on hCMEC/D3, HA, and
SH-SY5Yd (Figure S6). While the drug has little to no effect on
HA and hCMEC/D3, it seems to have an effect on SH-SY5Yd
cells (Figure S6), also at a concentration of 3 μM, exploited in
the Nut-Ang-LMNV testing; the previously observed absence
of cytotoxic effects when the SH-SY5Yd cells are treated with
Nut-Ang-LMNVs could be therefore ascribed to a low cellular
uptake, a hypothesis corroborated by the previously reported
targeting data.
Previous works demonstrated that nutlin-3a and other
MDM2 inhibitors are extremely effective on p53 wild-type
glioblastoma cell models, with little to no toxicity on several
healthy cells. For instance, Secchiero et al. showed that nutlin-
Figure 7. (A) Confocal analysis of the co-localization of Vybrant DiO-labeled Ang-LMNVs (in green) with lysosomes (in red) in U87 MG cells
after 24 and 72 h of treatment. (i) and (ii) represent zoomed areas (indicated by the yellow squares) of the merged confocal images at 24 and 72 h
of treatment, respectively; the white arrows indicate representative nanovector−lysosome co-localization. (B) Quantitative evaluation of co-
localization through Pearson’s correlation coefficient.
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3a is able to induce apoptosis in lymphoblastoid SKW6.4 cell
lines, but not in endothelial cells, even though an effect on
their cycle progression was observed at high drug concen-
trations.15 These findings are also confirmed by Shangary et al.
that compared the effect of an MDM2 inhibitor on normal and
cancer cells (CCD-18Co primary normal human colon
fibroblasts and RKO colon cancer cell line, respectively).52
The authors observed that the drug was able to induce both
cell cycle arrest and cell death in cancer cells, whereas in
healthy cells only cell cycle arrest was detected.52 However,
this strong sensitivity of cancer cells to MDM2 inhibitor
compared to healthy cells is still unclear. Some authors
suggested that the overexpression of the MDM2 protein in
cancer cells leads to a strong suppression of p53 and makes
them extremely vulnerable to p53 accumulation and
reactivation as soon as the MDM2 protein is inhibited. On
the other hand, normal cells have very low p53 basal levels;
therefore, the amount of active p53 reached after MDM2
inhibition is not high enough to induce apopostis.52
Alternating Magnetic Field Stimulation Effects. As
suggested by several studies, when magnetic nanoparticles are
efficiently internalized in lysosomes, the interaction between
these particles and the AMF may be detrimental for the
integrity of lysosomes, inducing a phenomenon known as
lysosome membrane permeabilization (LMP).20,21 Since Ang-
LMNVs are localized in lysosomes, we decided to investigate
whether the combination of Ang-LMNVs + AMF would lead
to LMP in U87 MG cells and to characterize this
phenomenon. U87 MG cells were incubated with Vybrant
DiO-labeled Ang-LMNVs (325 μg/mL) and lysosomes stained
with LysoTracker Deep Red. The cells were then stimulated
for 2 h with an AMF, and the fluorescence emission of
LysoTracker Deep Red was monitored in time-lapse imaging:
Figure 9A shows representative frames of this time-lapse
imaging (Videos S1−S3, Supporting Information). When the
control U87 MG cells (nonincubated with nanovectors)
undergo AMF stimulation, lysosomes do not experience any
visible qualitative modification, and LysoTracker Deep Red is
retained within the organelles. On the other hand, when cells
are pretreated with Ang-LMNVs, during the AMF stimulation,
the LysoTracker Deep Red signal starts to decrease (after
about 30 min), and it is completely lost after 90 min. This
decrement can suggest that LMP occurs, causing the leakage of
the fluorophore outside the organelles.21
The exploited tracer is however smaller than the proteolytic
enzymes contained in the lysosomal lumen. To verify that
damages provoked by Ang-LMNVs + AMF are strong enough
to allow lysosomal enzymes to spread into the cytosol, we
detected cathepsin B through immunofluorescence, before and
after AMF stimulation. As shown in Figure 9B, the decrement
of the fluorescence signal correlated to cathepsin B (red) after
AMF stimulation clearly indicates that the enzyme diffused
outside the lysosomes. In control cultures, when cells are
treated with Ang-LMNVs but not stimulated with the AMF,
cathepsin B has a strong signal with a good co-localization with
nanovectors, indirectly confirming their internalization in
lysosomes.
LMP is an important phenomenon involved in different cell
death mechanisms, and, for this reason, it has been proposed as
a new strategy to induce the initiation of death pathways in
resistant cancer cells.53 During LMP, the lysosomal proteases
are released into the cytosol, triggering apoptosis or non-
apoptotic pathways.54 Cathepsin B and D are identified as the
major actors in this process, being able to cleave Bid, a
proapoptotic protein of the Bcl-2 family, and starting a cascade
of events that lead to the release of cytochrome C from
mitochondria and to a caspase-dependent apoptosis mecha-
nism.55 LMP can also represent an important phenomenon in
cancer therapy because it favors the release of drugs
sequestered within the lysosomal compartment. It has been
demonstrated that the concentration of some drugs in
lysosomes is relatively high compared to other intracellular
locations,50,56 and drug sequestration by lysosomes represents
one of the causes of the development of multidrug resistance in
certain kind of cancer cells.57 The permeabilization of the
lysosomal membrane could counteract this process, eventually
favoring the escape of the drug in other cellular compartments
where it can play its pharmaceutical role.
The origin of LMP induced by the stimulation of SPIONs
with an AMF is still under study, and it is probably caused by
different phenomena, such as the SPION rotation or the heat
generation in the proximity of the lysosome membrane, that
Figure 8. (A) U87 MG cell viability after 24 and 72 h of treatment
with different concentrations of free nutlin-3a, plain Ang-LMNVs, and
Nut-Ang-LMNVs. All of the results were normalized to the respective
untreated control (CTRL). *p < 0.05. (B) Cell viability on different
cell lines (hCMEC/D3 in red; HA in green; SH-SY5Yd in blue; U87
MG in orange) 72 h after a 6 h treatment in dynamic conditions with
325 μg/mL of Nut-Ang-LMNVs (corresponding to a drug
concentration of 3 μM). All of the results were normalized to the
corresponding untreated controls (CTRL). *p < 0.05.
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lead to the degradation of the lipids composing the
membrane.19−21 However, the incidence of one of the two
mechanisms depends on the AMF parameters. It has been
previously shown that magnetic nanoparticles start to vibrate
or rotate when exposed to alternating magnetic fields of low
intensity and frequencies (2−16 Hz);58,59 on the other hand,
the interaction between SPIONs and an alternating magnetic
field at higher frequencies (in the order of hundreds of kHz)
gives rise to an increase of temperature (magnetic hyper-
thermia).60 It has been also demonstrated that the thermal
effect needed to induce a damage does not necessarily imply a
global increase in temperature of all of the cells, but it could be
limited to a selected area of the cell, such as lysosomes.
Previous results by our group demonstrated that LMNVs are
able to reach intraparticle temperature as high as 43 °C upon
stimulation with an AMF.18 This suggests that the LMP
induced by our nanovectors could be mainly driven by a local
increment of temperature inside lysosomes.
Hyperthermia treatments are often associated with an
alteration of the expression profile of heat shock proteins.61
In particular, the 70 kDa heat shock protein (Hsp70) is a
family of ubiquitous chaperon proteins, the expression of
which increases when cells are under stress conditions, in
particular thermal stress.62 Their role is to protect proteins
from unfolding, but they are also able to remodel the protein
structure during stress conditions63 to avoid apoptotic and
necrotic pathways.64 As demonstrated in many studies, Hsp70
chaperones are active in the cytosol, in the lumen of the
endoplasmic reticulum, and in mitochondrial membranes
where they help protein translocation across membranes.65
Figure 9. (A) Representative confocal time frames at t = 0, 86, and 120 min from the beginning of the treatment of U87 MG cells stimulated with
AMF, incubated with Ang-LMNVs, or stimulated with AMF in the presence of Ang-LMNVs. Vybrant DiO-labeled Ang-LMNVs in green,
lysosomes in red, and nuclei in blue. (B) Cathepsin B confocal imaging (in red) in U87 MG cultured upon different treatments. Vybrant DiO-
labeled Ang-LMNVs in green.
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Figure 10. Cell viability assessment in U87 MG cultures treated with Ang-LMNVs, Nut-Ang-LMNVs, or free nutlin-3a without (− AMF, red bars)
and with (+ AMF, green bars) AMF stimulation, (A) at the end of the stimulation and (B) after 3 days from the end of the stimulation (*p < 0.05).
Figure 11. Confocal imaging of p53 (in red) and Ki-67 (in green) expression and of nuclei (in blue) for all of the considered experimental classes
(A) just at end of the chronic stimulation and (B) after 3 days from the end of the stimulation. (C, D) Quantitative analysis of p53 and ki-67
localized in the nuclei (*p < 0.05).
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To assess any role in our experimental conditions, we
investigated the expression of Hsp70 in U87 MG cells upon
treatment with Ang-LMNVs + AMF. The results show that
U87 MG cells present a high basal level of Hsp70 (Figure S7).
This evidence is supported by several studies that highlight
how different types of cancer cells, in particular U87 MG, have
high levels of Hsp70 expression.66 The overexpression of
Hsp70 may be involved in the cell transformation and in the
deregulation of cell death pathways.64 Other works confirmed
that heat shock proteins are able to decrease the p53 levels
and, as a consequence, deregulate the apoptotic pathway.67 We
can see in Figure S7 that cells treated with Ang-LMNVs (with
or without AMF) have a similar level of Hsp70 fluorescence
signals compared to control cultures. On the other hand, when
cells are treated for 1 or 2 h at 42 °C, the increment of
fluorescence signal, correlated to an increase of Hsp70
expression, is qualitatively evident. We can thus conclude
that the stress induced by the treatment with Ang-LMNVs +
AMF does not result in an appreciable alteration of Hsp70
expression. Moreover, since Hsp70 has been shown to have a
crucial role in the protection of lysosomes of cancer cells
during stress stimuli,68 its unaltered expression could avoid
preventing the LMP induction and the following caspase-
activated apoptotic pathway. The unaltered Hsp70 levels also
confirm that the heat generated upon AMF stimulation gives
rise to a localized temperature increment, as previously
suggested. Moreover, as already pointed out, the TID
corresponding to a similar treatment (2D cell cultures exposed
LMNVs + AMF) is about 5 CEM43,18 a value that is probably
not high enough to stimulate an evident Hsp70 response. As a
comparison, in cells maintained at 42 °C for 2 h, with a TID
that is 6 times higher (30 CEM43), the Hsp70 expression
resulted evident.
Synergic Therapeutic Effects. The final aim of this work
was to investigate the synergic therapeutic effects obtained by
combining the use of nutlin-3a with the AMF stimulation of
SPIONs encapsulated in the nanovectors. To this aim, U87
MG cells were stimulated with an AMF chronic stimulation
protocol (2 h per day for 3 days), as already described.
As shown in Figure 10A, the AMF stimulation has a
dramatic effect on the cells treated with Ang-LMNVs and Nut-
Ang-LMNVs. Ang-LMNVs affect U87 MG cell viability only
when the AMF is applied. Nutlin-3a-loaded nanovectors,
instead, are already effective without the AMF stimulation, but
the application of the magnetic field decreases the metabolic
activity to almost 0.2 ± 1.6% (p < 0.05), meaning that the
combination of drug and AMF is extremely efficient in killing
cancer cells. Figure 10A also shows that AMF itself does not
affect cells in the absence of magnetic nanovectors.
To evaluate a possible recovery of the cells after the chronic
stimulation protocol, we performed cell viability assays on the
same experimental classes, but 3 days after the last AMF
Figure 12. (A) Activation of caspase-9 induced by AMF treatment combined with Ang-LMNVs or Nut-Ang-LMNVs administration to U87 MG
cells analyzed by flow cytometry and confocal microscopy (insets). The green spots correspond to activated caspase-9. (B) Quantitative analysis of
FITC-positive cells (%), corresponding to activated caspase-9, derived from flow cytometry (*p < 0.05).
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stimulation. The results in Figure 10B confirm that Ang-
LMNVs have no effect without AMF stimulation, whereas the
cells treated with Ang-LMNVs + AMF are not able to recover
when the insult is stopped. Cells treated with Nut-Ang-
LMNVs seem to slowly recover (cell metabolic activity
increases from 15.0 ± 0.8 to 34.0 ± 3.0% after 3 days);
once again, no recovery is observed upon AFM stimulation in
the presence of nanovectors.
Immunocytochemistry and confocal analysis were performed
to highlight the expression and localization of p53 and Ki-67
markers following AMF + Nut-Ang-LMNV treatment (Figure
11). A high localization of p53 in the nucleus is a hint that cells
are undergoing apoptosis. On the other hand, Ki-67 is used as
a proliferation marker since it can be found in nuclei during the
interphase of the cell cycle; a lack of expression of this marker
is detected during the G0 phase, where the cells are
quiescent.69 The confocal images and their corresponding
analysis to assess p53 and Ki-67 expression are shown in Figure
11. The plain AMF stimulation neither induces the activation
of nuclear p53 nor affects cell viability (Figure 11C,D). Plain
nutlin-3a has only a minor, non-AMF-dependent, effect in
activating the p53 pathway and in reducing cell viability
(Figure 11C); however, after 3 days from the end of the
treatment, no difference with respect to the control cultures
can be found (Figure 11D). The treatment with Ang-LMNVs
+ AMF results into a higher localization of p53 in the nuclei
(66.4 ± 21.9%) and in a lower expression of Ki-67 (18.8 ±
5.9%) compared to nonstimulated cells treated with Ang-
LMNVs (4.3 ± 1.6% for p53 and 62.5 ± 8.9% for Ki-67)
(Figure 11C). This difference is still maintained after 3 days
from the end of the stimulation protocol (Figure 11D).
Concerning Nut-Ang-LMNVs, there is no statistically sig-
nificant difference in the expression of the considered markers
between AFM-stimulated and nonstimulated cells right after
the end of the treatment (Figure 11C). In both cases, in fact,
there is a high localization of p53 in the nuclei (58.1 ± 18.6%
without AMF, 80.4 ± 14.2% with AMF) and a low Ki-67
expression (30.4 ± 11.7% without AMF, 16.4 ± 13.9% with
AMF) compared to control cells, suggesting that Nut-Ang-
LMNVs are able to induce apoptosis and reduce cell viability,
even in the absence of AFM stimulation. However, after 3 days
from the end of the AMF stimulation (Figure 11D), cultures
treated with Nut-Ang-LMNVs + AMF maintain a high level of
p53 (61.7 ± 18.6%) and low Ki-67 expression (20.9 ± 10.2%),
with respect to cells treated with Nut-Ang-LMNVs, but
without AFM stimulation (30.1 ± 2.4% for p53 and 56.0 ±
9.9% for Ki-67). Notably, the p53 co-localization with nuclei 3
days after the end of the chronic stimulation is higher in Nut-
Ang-LMNVs + AMF with respect to Ang-LMNVs + AMF
(61.7 ± 18.6 and 15.2 ± 10.2%, respectively). This is probably
due to the presence of the drug that is exerting its effect on the
small number of survived cells. We can thus speculate that the
higher p53 expression observed in the Nut-Ang-LMNVs +
AMF group 3 days after the end of the treatment could be due
to a higher release of nutlin-3a from the nanovectors upon
AMF stimulation, as seen in drug release studies, and to a drug
escape from lysosomes to cytosol induced by LMP. This result
clearly shows the importance of combining chemotherapy and
hyperthermia treatment.
Caspase-9 is an enzyme that acts as an initiator of the
apoptotic pathway induced by the release of cytochrome C
from mitochondria.70 Since this has been proposed as a
consequence of lysosomal cysteine proteases leakage after
LMP, we studied the activation of caspase-9 in U87 MG cells
in the same experimental classes considered for the p53 and
Ki-67 localization experiments. Figure 12 summarizes the
results obtained by both confocal microscopy and flow
cytometry. The presence of the activated enzyme in the cells
treated with Ang-LMNVs or Nut-Ang-LMNVs under stim-
ulation with AMF is highlighted by the green fluorescence of
FITC-Val-Ala-Asp-fluoro-methyl-rerone (FITC-VAD-FMK)
that interacts only with activated caspase-9 in apoptotic cells
(confocal acquisitions, insets in Figure 12A). This signal is
absent in control cells (+/− AMF), in cells treated with nutlin-
3a (+/− AMF), and in cells treated with Ang-LMNVs and
Nut-Ang-LMNVs without AMF stimulation. These results are
also confirmed by flow cytometry (Figure 12A, and relative
quantitative analysis in 12B). The treatment with Ang-LMNVs
or Nut-Ang-LMNVs coupled with AMF leads to a higher level
of FITC-positive cells, due to activated caspase-9 (19.9 ± 0.9%
for Ang-LMNVs and 22.7 ± 2.1% for Nut-Ang-LMNVs), with
respect to control cells (3.1 ± 0.8%) and to cells treated with
nanovectors without AMF (6.3 ± 1.4% for Ang-LMNVs and
9.4 ± 3.4% for Nut-Ang-LMNVs). The free drug has just a
minimal effect on the activation of caspase-9 (6.7 ± 2.4% for
nutlin-3a, 4.8 ± 0.5% for nutlin-3a + AMF). These evidences
suggest that the apoptosis induction through this pathway is
mainly due to the response of the magnetic component
subjected to the AMF.
The hyperthermia-induced LMP fosters the leakage of
proteolytic enzymes from the lysosomes and, as reported in
several works,54,55 induces cytochrome C release from
mitochondria, with consequent activation of the caspase-9
apoptotic pathway. The treatment with Nut-Ang-LMNVs
without AMF stimulus, instead, only results into the
reactivation of the p53 pathway, mediated by the interaction
between nutlin-3a and the MDM2 protein. As shown by these
results, the treatment with Ang-LMNVs + AMF is able to
activate both the caspase-9 and p53 pathways; however, Nut-
Ang-LMNVs + AMF are able to maintain the p53 apoptotic
effect also several days after the end of the stimulation, thanks
to the presence of the drug. This highlights the importance of
combining these two therapeutic approaches with the aim of
completely suppressing cancer cell viability and their
recurrence after the treatment.
■ CONCLUSIONS
In this work, we elucidated the mechanism of action of a lipid
magnetic nanovector loaded with a chemotherapeutic drug,
due to the synergic effect of nutlin-3a, a chemotherapy agent
with proved proapoptotic actions, and hyperthermia. In
particular, collected data show that Nut-Ang-LMNVs + AMF
stimulation induces localized intracellular effects that result in a
lysosomal damage. This leads, as a consequence, to a
proteolytic enzyme leakage that initiates several apoptotic
pathways and enhances the effects of the drug. The synergic
therapeutic approach makes the proposed nanovectors a
versatile platform to treat heterogeneous cancers like
glioblastoma multiforme. Finally, we demonstrated that the
functionalization with angiopep-2 is an excellent “dual-
targeting” strategy, allowing crossing of a complex BBB in
vitro model and high and specific accumulation in cancer cells.
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